Profile of BRAFV600E, BRAFK601E, NRAS, HRAS, and KRAS Mutational Status, and Clinicopathological Characteristics of Papillary Thyroid Carcinoma in Indonesian National Referral Hospital-Reference-Cited by-同舟云学术

Profile of BRAFV600E, BRAFK601E, NRAS, HRAS, and KRAS Mutational Status, and Clinicopathological Characteristics of Papillary Thyroid Carcinoma in Indonesian National Referral Hospital

Published:2023-05 Issue: Volume:Volume 16 Page:99-110
ISSN:1178-704X
Container-title:The Application of Clinical Genetics
language:en
Short-container-title:TACG

Author:

Harahap Agnes Stephanie,Subekti Imam,Panigoro Sonar Soni,Asmarinah -^ORCID,Lisnawati -,Werdhani Retno Asti^ORCID,Agustina Hasrayati^ORCID,Khoirunnisa Dina^ORCID,Mutmainnah Mutiah^ORCID,Salinah -,Siswoyo Alvita Dewi,Ham Maria Francisca

Publisher

Informa UK Limited

Subject

Genetics (clinical),Genetics

Reference57 articles.

1. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013

2. Epidemiology of Thyroid Cancer: A Review of the National Cancer Database, 2000-2013

3. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

4. WHO Classification of Tumors Editorial Board. Endocrine and neuroendocrine tumors. Lyon (France): international Agency for Research on Cancer; 2022. Available from: https://tumourclassification.iarc.who.int/chapters/53. Accessed May 19, 2023.

5. BRAF Mutation in Papillary Thyroid Carcinoma: Pathogenic Role and Clinical Implications

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Developing Models to Predict BRAFV600E and RAS Mutational Status in Papillary Thyroid Carcinoma Using Clinicopathological Features and pERK1/2 Immunohistochemistry Expression;Biomedicines;2023-10-16